FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135607195> ?p ?o ?g. }

• W2135607195 endingPage "787" @default.
• W2135607195 startingPage "777" @default.
• W2135607195 abstract "IN the spring of 2007, a 2-year clinical drug trial began at Children’s Hospital Boston (1) with the goal to advance the quality of life for children with Hutchinson-Gilford progeria syndrome (henceforth progeria), a rare (frequency 1 in 4 million), multisystem, and inevitably fatal disease that claims young lives due to myocardial infarctions and strokes between ages 7 and 20 years (2). The journey to the first clinical trial for progeria has been facilitated by a series of collaborative scientific workshops organized by The Progeria Research Foundation (PRF) and supported by agencies interested in aging, cardiovascular disease, rare disease research, and genetics (http://www.progeriaresearch. org/2007_prf_workshop_on_progeria.html). These meetings have provided a concentrated forum to facilitate the collective thinking of clinicians and scientists about progeria, forge collaborations in this little-known field, and accelerate the discovery of new ways to push the field forward toward treatments and cure. The first PRF Scientific Workshop in 2001 helped to identify nuclear blebbing as an important phenotypic marker of progeria cells (noted by Anthony Weiss; University of Sydney, Australia), and to recognize a translocation on chromosome 1 in the cells cultured from a progeria patient (W. Ted Brown, New York State Institute for Basic Research in Developmental Disabilities), pointing geneticists in the direction of the gene mutation for progeria (3). In 2003, the second workshop was held just 3 months after publication of the gene defect in progeria, which is typically a sporadic autosomal dominant disease caused by a C ! T mutation at nucleotide 1824 of the LMNA gene encoding lamin A (4,5). Importantly, the mutation results in a persistence of an aberrant form of a farnesylated-prelamin A molecule (4) now called progerin. The attendees now included experts in the field of lamin biology and laminopathies. The 2004 Progeria Workshop, held within the National Human Genome Research Institute (NHGRI), was held specifically to discuss the role of stem cells and the potential for stem cell transplantation in progeria, an area of continuing interest for the field. At the general Progeria Workshop in 2005, two mouse models of progeria were unveiled and, although they contained identical mutations, they yielded very different phenotypes, mimicking various portions of the human disease (6,7). Early in vitro data on a potential role of farnesyltransferase inhibitors (FTIs) in treating progeria were presented by four laboratories, demonstrating that FTI could reverse nuclear blebbing in cells expressing progerin (8–11). Armed with data demonstrating that treatment of newly developed cellular assays with FTIs improves or reverses some of the effects of progerin accumulation, a clinical trial treating children with progeria with an FTI was initiated in May 2007 (1) (www.clinicaltrials.gov). The present article, detailing the 2007 PRF Scientific Workshop (November 12–14, Boston), emphasizes the complexities of progerin and lamin A biology, and the need to continue to look for the most effective protocols for correcting the effects of the lamin A defect in progeria. All speakers presented preliminary data that had not been peerreviewed at the time of presentation. In the months since the workshop, some data have been published (referenced within this article), and we look forward to additional peerreviewed publications on the work presented at this meeting over the coming year. The essence of translational research was represented in the presentations, which brought forth the most important issues in progeria today—the effects of progerin and lamins and their binding partners on the functioning of cells, systems, mouse models, and humans; the connection between progeria, aging, and cardiovascular disease in the general population; careful analysis of FTI effects on progeria at all levels (summarized in Table 1); and strategies for future disease treatments and cure. In his introduction at the workshop, Francis Collins (Director, NHGRI) noted that a 4-year period between gene discovery and a clinical drug trial is ‘‘. . . an unprecedented feat for a rare genetic disease.’’ For progeria patients and their families, who have struggled to live within a void of information, the clinical trial represents ‘‘. . . a source of light coming up after a long, long night’’ and hope has replaced ‘‘. . . a sense of fear and helplessness on each passing birthday’’ (Subbarao, father of Priya, a 15year-old with progeria)." @default.
• W2135607195 created "2016-06-24" @default.
• W2135607195 creator A5005792150 @default.
• W2135607195 creator A5006471805 @default.
• W2135607195 creator A5053997423 @default.
• W2135607195 date "2008-08-01" @default.
• W2135607195 modified "2023-10-18" @default.
• W2135607195 title "Highlights of the 2007 Progeria Research Foundation Scientific Workshop: Progress in Translational Science" @default.
• W2135607195 cites W1482978110 @default.
• W2135607195 cites W1819718829 @default.
• W2135607195 cites W1909554228 @default.
• W2135607195 cites W1964551999 @default.
• W2135607195 cites W1965824330 @default.
• W2135607195 cites W1966645907 @default.
• W2135607195 cites W1970338621 @default.
• W2135607195 cites W1970924670 @default.
• W2135607195 cites W1974449792 @default.
• W2135607195 cites W1985981012 @default.
• W2135607195 cites W1998663807 @default.
• W2135607195 cites W2001614140 @default.
• W2135607195 cites W2002569327 @default.
• W2135607195 cites W2022487205 @default.
• W2135607195 cites W2023569444 @default.
• W2135607195 cites W2029517875 @default.
• W2135607195 cites W2031866174 @default.
• W2135607195 cites W2032840484 @default.
• W2135607195 cites W2038028886 @default.
• W2135607195 cites W2040205289 @default.
• W2135607195 cites W2043428749 @default.
• W2135607195 cites W2043446752 @default.
• W2135607195 cites W2043934275 @default.
• W2135607195 cites W2048445712 @default.
• W2135607195 cites W2050838528 @default.
• W2135607195 cites W2052011655 @default.
• W2135607195 cites W2053206914 @default.
• W2135607195 cites W2053497997 @default.
• W2135607195 cites W2071870365 @default.
• W2135607195 cites W2072810104 @default.
• W2135607195 cites W2073460054 @default.
• W2135607195 cites W2073509406 @default.
• W2135607195 cites W2079642003 @default.
• W2135607195 cites W2083296702 @default.
• W2135607195 cites W2093355627 @default.
• W2135607195 cites W2094806530 @default.
• W2135607195 cites W2099194160 @default.
• W2135607195 cites W2103286704 @default.
• W2135607195 cites W2111163029 @default.
• W2135607195 cites W2118898403 @default.
• W2135607195 cites W2123704670 @default.
• W2135607195 cites W2127708563 @default.
• W2135607195 cites W2134267224 @default.
• W2135607195 cites W2136237360 @default.
• W2135607195 cites W2138896629 @default.
• W2135607195 cites W2141334538 @default.
• W2135607195 cites W2142780571 @default.
• W2135607195 cites W2143185290 @default.
• W2135607195 cites W2143571321 @default.
• W2135607195 cites W2145283260 @default.
• W2135607195 cites W2148221837 @default.
• W2135607195 cites W2148618665 @default.
• W2135607195 cites W2149619603 @default.
• W2135607195 cites W2162219284 @default.
• W2135607195 cites W2167960257 @default.
• W2135607195 doi "https://doi.org/10.1093/gerona/63.8.777" @default.
• W2135607195 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18772465" @default.
• W2135607195 hasPublicationYear "2008" @default.
• W2135607195 type Work @default.
• W2135607195 sameAs 2135607195 @default.
• W2135607195 citedByCount "13" @default.
• W2135607195 countsByYear W21356071952012 @default.
• W2135607195 countsByYear W21356071952014 @default.
• W2135607195 countsByYear W21356071952017 @default.
• W2135607195 crossrefType "journal-article" @default.
• W2135607195 hasAuthorship W2135607195A5005792150 @default.
• W2135607195 hasAuthorship W2135607195A5006471805 @default.
• W2135607195 hasAuthorship W2135607195A5053997423 @default.
• W2135607195 hasBestOaLocation W21356071951 @default.
• W2135607195 hasConcept C104317684 @default.
• W2135607195 hasConcept C127413603 @default.
• W2135607195 hasConcept C128544194 @default.
• W2135607195 hasConcept C142724271 @default.
• W2135607195 hasConcept C144024400 @default.
• W2135607195 hasConcept C17744445 @default.
• W2135607195 hasConcept C199539241 @default.
• W2135607195 hasConcept C2778465436 @default.
• W2135607195 hasConcept C2780966255 @default.
• W2135607195 hasConcept C36289849 @default.
• W2135607195 hasConcept C54355233 @default.
• W2135607195 hasConcept C55587333 @default.
• W2135607195 hasConcept C57634137 @default.
• W2135607195 hasConcept C71924100 @default.
• W2135607195 hasConcept C86803240 @default.
• W2135607195 hasConceptScore W2135607195C104317684 @default.
• W2135607195 hasConceptScore W2135607195C127413603 @default.
• W2135607195 hasConceptScore W2135607195C128544194 @default.
• W2135607195 hasConceptScore W2135607195C142724271 @default.
• W2135607195 hasConceptScore W2135607195C144024400 @default.
• W2135607195 hasConceptScore W2135607195C17744445 @default.

• next